Venetoclax-Azacitidine Versus Azacitidine for the Treatment of Primary Refractory or First Relapsed Acute Myeloid Leukemia. An IPC-DATAML-MSKCC Retrospective Study

被引：0
|
作者：
Petit, Cassandre [1 ]
Higue, Jules [2 ]
Acheaibi, Ziyad [3 ]
Gilhodes, Julia [1 ]
Hospital, Marie-Anne [1 ]
Devillier, Raynier [1 ]
Bewersdorf, Jan [4 ]
Goldberg, Aaron D. [4 ]
Pigneux, Arnaud [3 ]
Vey, Norbert [1 ]
Recher, Christian [2 ]
Stahl, Maximilian [4 ]
Bertoli, Sarah [2 ]
Dumas, Pierre-Yves [3 ]
Garciaz, Sylvain [1 ]
机构：
[1] Aix Marseille Univ, CNRS, INSERM, Inst Paoli Calmettes,CRCM, Marseille, France
[2] Univ Toulouse, Ctr Hosp Univ Toulouse, Inst Univ Canc Toulouse Oncopole, Ctr Rech Cancerol Toulouse, Toulouse, France
[3] Univ Bordeaux, BRIC BoRdeaux Inst Oncol, Serv Hematol Clin & Therapie Cellulaire, CHU Bordeaux,INSERM,UMR1312, Bordeaux, France
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Div Hematol Malignancies, New York, NY USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2025年 / 100卷 / 05期
关键词：
azacitidine; leukemia; relapsed/refractory AML; venetoclax; AML; OUTCOMES; PHASE-3;
D O I：
10.1002/ajh.27626
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：906 / 908
页数：3
相关论文
共 50 条
  • [1] Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
    Bouligny I.M.
    Murray G.
    Doyel M.
    Patel T.
    Boron J.
    Tran V.
    Gor J.
    Hang Y.
    Alnimer Y.
    Ho T.
    Zacholski K.
    Venn C.
    Wages N.A.
    Grant S.
    Maher K.R.
    Medical Oncology, 41 (3)
  • [2] Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia
    Che, Yue
    Tan, Wanqing
    Liu, Ying
    Liu, Haitao
    Li, Lanlan
    Qin, Fangmei
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01) : 209 - 214
  • [3] Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients
    Petit, C.
    Saillard, C.
    Mohty, B.
    Hicheri, Y.
    Villetard, F.
    Maisano, V.
    Charbonnier, A.
    Rey, J.
    D'Incan, E.
    Rouzaud, C.
    Gelsi-Boyer, V.
    Murati, A.
    Lhoumeau, A. C.
    Ittel, A.
    Mozziconacci, M. J.
    Alary, A. S.
    Hospital, M. -A.
    Vey, N.
    Garciaz, S.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 112 (04) : 530 - 537
  • [4] Activity of Azacitidine and Venetoclax Compared to Other Therapies in Adults with Refractory or Relapsed Acute Myeloid Leukemia, a Retrospective Study
    Pelland, Andree-Anne
    Savard, Xavier
    Barabe, Frederic
    Laroche, Vincent
    Munger, Michael
    Gallagher, Genevieve
    Marcoux, Nicolas
    Cantin, Guy
    Chenard-Poirier, Maxime
    Delage, Robert
    Lalancette, Marc
    Lemieux, Christopher
    BLOOD, 2022, 140 : 3304 - 3305
  • [5] Fix low dose venetoclax-azacitidine treatment of unfit acute myeloid leukemia patients
    Miklos, Egyed
    Oliver, Toth Peter
    Adam, Kellner
    Eva, Karadi
    Balazs, Kollar
    Eszter, Kovacs
    Anett, Pavlovics
    Viktoria, Gyori-Korom
    Jozsef, Herczeg
    Peter, Rajnics
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (02) : 183 - 189
  • [6] Azacitidine in Patients with Relapsed/Refractory Acute Myeloid Leukemia : Retrospective Analysis of the Austrian Azacitidine Registry
    Pleyer, Lisa
    Burgstaller, Sonja
    Stauder, Reinhard
    Girschikofsky, Michael
    Linkesch, Werner
    Pfeilstoecker, Michael
    Autzinger, Eva Maria
    Tinchon, Christoph
    Sliwa, Thamer
    Lang, Alois
    Sperr, Wolfgang R.
    Geissler, Dietmar
    Krippl, Peter
    Voskova, Daniela
    Rossmann, Dieter H.
    Schlick, Konstantin
    Thaler, Josef
    Halter, Britta
    Machherndl-Spandl, Sigrid
    Theiler, Georg
    Valent, Peter
    Eckmuellner, Otto
    Greil, Richard
    BLOOD, 2014, 124 (21)
  • [7] A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia
    Murthy, Guru Subramanian Guru
    Saliba, Antoine N.
    Szabo, Aniko
    Harrington, Alexandra
    Abedin, Sameem
    Carlson, Karen
    Michaelis, Laura
    Runaas, Lyndsey
    Baim, Arielle
    Hinman, Alex
    Maldonado-Schmidt, Sonia
    Venkatachalam, Annapoorna
    Flatten, Karen S.
    Peterson, Kevin L.
    Schneider, Paula A.
    Litzow, Mark
    Kaufmann, Scott H.
    Atallah, Ehab
    HAEMATOLOGICA, 2024, 109 (09) : 2864 - 2872
  • [8] Azacitidine, intensive chemotherapy or best supportive care in relapsed or refractory acute myeloid leukemia, a DATAML registry study
    Gadaud, Noemie
    Leroy, Harmony
    Berard, Emilie
    Tavitian, Suzanne
    Leguay, Thibaut
    Dimicoli-Salazar, Sophie
    Rieu, Jean-Baptiste
    Luquet, Isabelle
    Largeaud, Laetitia
    Bidet, Audrey
    Delabesse, Eric
    Klein, Emilie
    Sarry, Audrey
    De Grande, Anne-Charlotte
    Bories, Pierre
    Pigneux, Arnaud
    Recher, Christian
    Dumas, Pierre-Yves
    Bertoli, Sarah
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1398 - 1406
  • [9] Prediction of Volasertib Sensitivity in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax Plus Azacitidine
    Patil, Lokesh
    Gu, Christine J.
    Tognon, Cristina
    Long, Nicola
    Johnson, Kara
    Fischer, Melissa A.
    Ball, Somedeb
    Savona, Michael R.
    Leonardi, Chris
    Wagner, Joseph
    Michelson, Glenn
    Lacher, Markus D.
    BLOOD, 2024, 144 : 5818 - 5819
  • [10] Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed/Refractory Acute Myeloid Leukemia
    Yu, Guopan
    Xu, Na
    Huang, Fen
    Fan, Zhiping
    Liu, Hui
    Shi, Pengcheng
    Zhou, Hongsheng
    Wang, Zhixiang
    Zhang, Yu
    Liu, Qifa
    BLOOD, 2020, 136
12345